BPC-157
BPC-157 is an investigational synthetic peptide widely discussed for tissue repair. Human evidence remains very limited, and Canadian authorities warn about unauthorized peptide products.
Independent Canadian research · Evidence first · No products sold
Research library
Understand compound mechanisms, evidence quality, safety limitations and Canadian regulatory status. Filter by research area or search a compound by name.
4 published peptides found
BPC-157 is an investigational synthetic peptide widely discussed for tissue repair. Human evidence remains very limited, and Canadian authorities warn about unauthorized peptide products.
Copper peptide biology, skin research, evidence quality and Canadian regulatory context.
Semaglutide is a GLP-1 receptor agonist with clinical trial evidence for metabolic outcomes and authorized Canadian prescription products. Indications and product approvals are formulation-specific.
Tirzepatide is a dual GIP/GLP-1 receptor agonist studied in major human clinical trials. Health Canada lists authorized prescription products, while unauthorized online copies require careful distinction.